We would love to hear your thoughts about our site and services, please take our survey here.
BBC News - their initial sensational reporting has a lot to answer for - as we know it was clearly fake news; many people were motivated to invest on the back of this 'Klondyke' ye ha.... What a shambles.
RNS Statement is somewhat confusing and contradictory and employs reductive vocabulary; so what separates the issues with this case from potential other cases in currently in process? Is this a positive explanation? What do others think here?
No surprises here this Morning in this RNS and SP should at least hold steady over coming days. IMHO, future growth opportunity lies ahead for Persimmon, especially where accommodation demands outstrips supply and availability; this share still remains a relatively sound future investment with a reasonable Divi too, which may well increase again in the short term.
Re Todays RNS
Noticed that a Susan Marsden also resigned a few days ago from this ConvaTec Finance Holdings Limited and wonder if there is a connection with Richard Marsden? Could be to avoid potential conflict of issue? Could be coincidental and irrelevant or planned and relevant - who knows?
Aired this morning at 06.32 - 'Fracking - The Fault Line' - Special Sky News Report
Asking the Scientists to take another look - some suggestion that Government may have been over cautious
Both sides of the eco arguments were discussed
Discussion points included 'is it worth the risk'
'Mixed with politics - is it worth the cost'
'Are we shipping away opportunities abroad with what lies under our feet'
'British Geological Society finalising their report and Govt want to be ' guided by the science'
Worth a watch on Sky Catch Up
Second attempt copy/paste
Synairgen PLC (AIM:SNG, OTC:SYGGF) CEO Richard Marsden joins Proactive London's Katie Pilbeam after the news that their antiviral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.
The external data safety monitoring board of the ACTIV-2 study recommended Synairgen’s SNG001 go to Phase III trials in mild to moderate COVID-19 patients. SNG001 is a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta, a naturally occurring protein that orchestrates the body's antiviral responses.
As well as the ACTIV-2 trial, Marsden updates on their own Phase III trial, called SPRINTER, which is assessing SNG001 in hospitalised COVID-19 patients and expects to publish top-line results in early 2022.
This is what I read - is this it?
Synairgen PLC (AIM:SNG, OTC:SYGGF) CEO Richard Marsden joins Proactive London's Katie Pilbeam after the news that their antiviral treatment for severe lung infections will advance to the final stage of trials as part of a US government-sponsored programme.
The external data safety monitoring board of the ACTIV-2 study recommended Synairgen’s SNG001 go to Phase III trials in mild to moderate COVID-19 patients. SNG001 is a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta, a naturally occurring protein that orchestrates the body's antiviral respo